Board of Directors

Wendy Yarno
Chairperson of Aratana Therapeutics

Prior to joining Aratana’s Board of Directors, Wendy Yarno, held positions of increasing responsibility and was responsible for leading multiple business groups during her 26-year career at Merck & Co, Inc. Most recently, she served as Chief Marketing Officer where she led the global organization charged with all aspects of supporting pre-and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. Ms. Yarno also served as Merck’s Senior Vice President of Human Resources, where her successful efforts to develop and implement new corporate personnel strategies proved transformative for this key business function. Ms. Yarno was also Vice President of Johnson & Johnson, Ortho McNeil Pharmaceutical’s highly profitable Women’s Health Care Franchise. Ms. Yarno is currently a director of St. Jude Medical, a Fortune 500 publicly-traded medical device company and Medivation, Inc., a publicly-traded biopharmaceutical company. Ms. Yarno received an M.B.A. from the Fox School of Business at Temple University and a B.S. in business administration from Portland State University.

 

Steven St. Peter, M.D.
President and CEO, Aratana Therapeutics

Steven St. Peter was previously a Managing Director at MPM Asset Management Company LLC where he led the investment in and served as Chairman of Aratana Therapeutics. While at MPM, his investment scope included both venture and buyout transactions across the pharmaceutical and medical technology industries. His investment experience includes positions at Apax Partners and The Carlyle Group. Previously, Dr. St. Peter was Assistant Clinical Professor of Medicine at Columbia University. Dr. St. Peter currently serves on the Board of Directors of publicly-traded PharmAthene, Inc. He has also served on the Board of Directors for both the Kansas City Area Life Sciences Institute since March 2014 and the Greater Kansas City Foundation since November 2015. He received a Doctor of Medicine degree from Washington University and completed his residency and fellowship at the Hospital of the University of Pennsylvania. He also holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas.

 

Laura A. Brege

Laura Brege is currently Managing Director of Cervantes Life Sciences Partners, LLC, a healthcare advisory and consulting company. She also served as President and Chief Executive Officer of Nodality, Inc., a privately-held life sciences company and prior to joining Nodality, Ms. Brege held various positions of responsibility at Onyx Pharmaceuticals, Inc., including most recently, Executive Vice President of Corporate Affairs. Ms. Brege’s previous experience also includes serving as a General Partner at Red Rock Capital Management, a venture capital firm, and as Chief Financial Officer at companies such as COR Therapeutics, Inc., a biotechnology company, and Flextronics, Inc., a supply-chain solutions company. Ms. Brege currently serves on the board of directors of publicly-traded Acadia Pharmaceuticals, Inc., Dynavax Technologies Corporation, Pacira Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degrees from Ohio University and has an M.B.A. from the University of Chicago.

 

David L. Brinkley

David Brinkley worked for Theravance, Inc., a biopharmaceutical company, from 2000 to 2013, most recently as the Head of Business Development from November 2008 to July 2013. Mr. Brinkley had previously served as Senior Vice President, Commercial Development at Theravance when he left to start a consulting practice in 2007. Prior to that, he served as Worldwide Team Leader for Viagra at Pfizer Inc., leading the team that had full responsibility for the global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham’s Animal Health operations and was Director of new product planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline Animal Health from 1983 to 1995. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.

 

Robert “Rip” B. Gerber, Jr. 

Rip Gerber currently serves as Chief Marketing Officer and Head of Alliances at Vlocity, Inc., a software company. He was also the founder of “Location-as-a-Service” (LaaS) and built Locaid into the world’s largest LaaS platform. Prior to Locaid, Rip served in senior executive roles at various public and private companies including Carlson, Intellisync and Nokia. At Nokia, he served as General Manager and Chief Marketing Officer of Intellisync, where he’s recognized for transforming the company’s brand and products and orchestrating the $510M acquisition by Nokia. Prior to that, he served as Senior Vice President at Carlson, a $38 billion company and one of the largest family-held corporations in the United States. Rip was also on the founding executive team of Commtouch, where, as Chief Marketing Officer, he was a lead executive in taking the company public in 1999. Earlier in his career, Rip founded @once, an email marketing company that was later acquired by InfoUSA. He also served in engineering and management roles at Deloitte Consulting, American Express and Firestone Tire & Rubber. Rip currently serves on the board of LocationSmart, a location software company and on the board of trustees of Drew School, a private high school located in San Francisco. Rip is a noted mobile industry visionary, entrepreneur, public company executive and international best-selling author. His thrillers have been published by Random House and Forge. He holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from the University of Virginia.

 

Irvine “Irv” O. Hockaday, Jr., J.D.

Irv Hockaday is the retired president and chief executive officer of Hallmark Cards, Inc. Prior to joining Hallmark in 1983, Mr. Hockaday served as president and chief executive officer of Kansas City Southern Industries, Inc. He was a member of the Hallmark board of directors from 1978 through 2001. Mr. Hockaday is lead director of The Estee Lauder Companies, Inc. and chair of its audit committee. He is a former director or lead director of Crown Media Holdings, Inc., Dow Jones & Company, Inc., Ford Motor Company and Sprint Nextel Corporation. He currently holds various civic positions including trustee of the Hall Family Foundation and board member of Kansas City Area Life Sciences Institute and has previously served as chairman of the board of the Tenth District Federal Reserve Bank. Mr. Hockaday earned his A.B. in English from Princeton University and his J.D. from the University of Michigan Law School.

 

Merilee Raines

Merilee Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly-traded company providing diagnostic and IT products and services primarily to the companion animal health market from October 2003 until her retirement in May 2013. Ms. Raines also served as Executive Vice President of IDEXX Laboratories from July 2012 to May 2013, and as Corporate Vice President, Finance of IDEXX Laboratories from May 1995 to July 2012. Ms. Raines is currently a director of Watts Water Technologies, Inc., a publicly-traded manufacturer of products and systems focused on control, conservation and quality of water. Ms. Raines earned a bachelor’s degree in mathematics from Bowdoin College and an M.B.A. from the University of Chicago.

 

Robert P. Roche, Jr.

Robert Roche is the founding member of Robert Roche Associates, LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries. Mr. Roche created this firm upon his retirement from Cephalon, Inc., a biopharmaceutical company, in February 2010. Mr. Roche joined Cephalon in January 1995 as the Vice President of Sales and Marketing and was named Executive Vice President, Worldwide Pharmaceutical Operations of Cephalon in 2005. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development, for SmithKline Beecham’s central nervous system and gastrointestinal products business. Mr. Roche also was managing director of SmithKline’s pharmaceutical operations in the Philippines. Prior to that, he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline as a U.S. pharmaceutical sales representative. Mr. Roche is currently a director of Antares Pharma, Inc., a publicly-traded specialty pharmaceutical company. He formerly served as a director of LifeCell Corp. until its acquisition in 2008, EKR Therapeutics until its acquisition in 2012, NuPathe Inc. until its acquisition in February 2014 and Civitas Therapeutics until its acquisition in November 2014. He also serves on the boards of Bryn Mawr Hospital and Westtown School. Mr. Roche earned his B.A. from Colgate University and his M.B.A. from The Wharton School at the University of Pennsylvania.

 

John Vander Vort, J.D.

John W. Vander Vort is currently a Managing Director at Pilot House Associates, LLC, a family investment office based in Boston, which he joined in September 2014. Prior to this role, Mr. Vander Vort was a Managing Director and the Chief Operating Officer of Charlesbank Capital Partners, a private equity firm. Mr. Vander Vort joined Charlesbank in September 2013 from MPM Asset Management LLC, one of the world’s largest venture capital firms focused on the life science industry. Before joining MPM in 2005, John was a Director in the Private Markets Group at DuPont Capital Management. Previously, he was a General Partner and Co-Founder of BlueStream Ventures and a Managing Director at Dain Rauscher Wessels (now the Royal Bank of Canada), where he led the West Coast Networking and Communications Investment Banking Group and served as an advisor to leading venture-backed technology companies. Mr. Vander Vort began his career as a corporate transaction attorney in the San Francisco office of Cooley Godward, where he represented venture capital firms and venture-backed companies. Mr. Vander Vort earned his B.A. from Amherst College and his J.D. from The University of Chicago Law School.